Evidence map›Paper›PMID 39928579›Full record

Trial reportPloS one2025

The impact of Duration of Untreated Psychosis on functioning and quality of life over one year of Coordinated Specialty Care (CSC).

Hadar Hazan, Sümeyra N Tayfur, Bin Zhou, Fangyong Li, Toni Gibbs-Dean, Sneha Karmani, Emily Kline, Maria Ferrara, Silvia Corbera, Sarah Riley and 4 more

Abstract readClinical Trial
In one paragraph

Trial report in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hadar HazanDepartment of Psychiatry, Yale University School of Medicine, and Program for Specialized Treatment Early in Psychosis (STEP), New Haven, Connecticut, United States of America.ORCID 0000-0001-7846-9624
Sümeyra N TayfurDepartment of Psychiatry, Yale University School of Medicine, and Program for Specialized Treatment Early in Psychosis (STEP), New Haven, Connecticut, United States of America.ORCID 0000-0002-5151-850X
Bin ZhouYale Center for Analytical Sciences, Yale School of Public Health, New Haven, Connecticut, United States of America.
Fangyong LiYale Center for Analytical Sciences, Yale School of Public Health, New Haven, Connecticut, United States of America.
Toni Gibbs-DeanDepartment of Psychiatry, Yale University School of Medicine, and Program for Specialized Treatment Early in Psychosis (STEP), New Haven, Connecticut, United States of America.
Sneha KarmaniDepartment of Psychiatry, Yale University School of Medicine, and Program for Specialized Treatment Early in Psychosis (STEP), New Haven, Connecticut, United States of America.
Emily KlineDepartment of Psychiatry, Harvard Medical School, Beth Israel Deaconess Medical Center, and Massachusetts Mental Health Center, Boston, Massachusetts, United States of America.
Maria FerraraUniversity of Ferrara, Ferrara, Italy.
Silvia CorberaDepartment of Psychological Science, Central Connecticut State University, New Britain, Connecticut, United States of America.ORCID 0000-0002-5090-2462
Sarah RileyDepartment of Psychiatry, Yale University School of Medicine, and Program for Specialized Treatment Early in Psychosis (STEP), New Haven, Connecticut, United States of America.ORCID 0000-0002-2748-9833
Laura A Yoviene SykesDepartment of Psychiatry, Yale University School of Medicine, and Program for Specialized Treatment Early in Psychosis (STEP), New Haven, Connecticut, United States of America.
Cenk TekDepartment of Psychiatry, Yale University School of Medicine, and Program for Specialized Treatment Early in Psychosis (STEP), New Haven, Connecticut, United States of America.
Matcheri S KeshavanDepartment of Psychiatry, Harvard Medical School, Beth Israel Deaconess Medical Center, and Massachusetts Mental Health Center, Boston, Massachusetts, United States of America.
Vinod H SrihariDepartment of Psychiatry, Yale University School of Medicine, and Program for Specialized Treatment Early in Psychosis (STEP), New Haven, Connecticut, United States of America.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
STEP-ED:Reducing Duration of Untreated Psychosis and its Impact in the U.S.R01MH103831 · NIMH · YALE UNIVERSITY · PI SRIHARI, VINOD H. · 2013 to 2017
$3.9M
NCATS NIH HHS UL1 TR001863NIMH NIH HHS R01 MH103831
6 · The paper itself

Abstract

backgroundThis study examined the relationship between the Duration of Untreated Psychosis (DUP) and functional outcomes at baseline, 6 months, and 12 months after admission to Coordinated Specialty Care (CSC).

methodsA total of 246 participants from two U.S. public-sector CSC programs were categorized into Low and High DUP groups using two criteria: (i) a median split of the DUP distribution and (ii) the World Health Organization (WHO) aspirational standard of 3 months. Changes in global functioning (GAF), social functioning (GF: Social), and occupational functioning (GF: Role), symptom severity (PANSS), and quality of life (QoL) were assessed using a Linear Mixed Model Repeated Measures (MMRM) analysis across the three time points. A Generalized Linear Model (GLM) with a logit link function was applied to analyze binary outcomes, specifically the status of being Neither in the Labor Force, Education, or Training (NLFET). Both models adjusted for time and site as covariates and used an unstructured variance-covariance matrix to account for within-subject correlations in repeated measures. The difference-in-differences method was employed to estimate the impact of DUP on outcomes over time, with results reported as least square means for continuous outcomes, odds ratios for binary outcomes, and 95% confidence intervals (CI) for both Low and High DUP groups.

resultsNo significant differences were observed between the Low and High DUP groups at baseline. By 6 months, participants in the Low DUP group (DUP < 3 months) exhibited significantly greater improvements (reduction) in NLFET status (3-month OR = 3.25, p = 0.03; median split OR = 2.25, p = 0.03) and global functioning, GF: Role, and GF: Social. By 12 months, the Low DUP group continued to show significantly greater NLFET status improvement (3-month OR = 3.59, p = 0.03; median split OR = 3.40, p = 0.0032). Improvements in global functioning were sustained at 12 months, while social and occupational functioning gains were not. No significant differences were observed between groups for quality of life or symptom severity over time.

conclusionShorter DUP is linked to more rapid functional recovery within the first year after CSC admission.

Indexed as

Community PsychiatryPsychotic DisordersQuality of LifeSchizophreniaEmploymentFemaleFollow-Up StudiesHumansMaleNon-Randomized Controlled Trials as TopicPsychosocial FunctioningSeverity of Illness IndexSocial InteractionTime FactorsYoung Adult

Identifiers

PMID39928579
PMCPMC11809850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.